An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors
收藏DataCite Commons2025-10-31 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008601/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab in
combination with bevacizumab, bevacizumab + oxaliplatin, leucovorin and 5-fluorouracil (5-FU)
(FOLFOX), vanucizumab, nab-paclitaxel + gemcitabine, FOLFOX, or 5-FU + cisplatin, in
participants with solid tumors.
提供机构：
Vivli
创建时间：
2022-11-23
